Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally.
Syngene International Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹548.85|
|52 Week High||₹490.35|
|52 Week Low||₹699.95|
|1 Month Change||-13.54%|
|3 Month Change||-12.25%|
|1 Year Change||0.49%|
|3 Year Change||91.62%|
|5 Year Change||95.60%|
|Change since IPO||253.64%|
Recent News & Updates
|539268||IN Life Sciences||IN Market|
Return vs Industry: 539268 underperformed the Indian Life Sciences industry which returned 46.8% over the past year.
Return vs Market: 539268 underperformed the Indian Market which returned 62.5% over the past year.
Stable Share Price: 539268 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 539268's weekly volatility (4%) has been stable over the past year.
About the Company
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services.
Syngene International Fundamentals Summary
|539268 fundamental statistics|
Is 539268 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|539268 income statement (TTM)|
|Cost of Revenue||₹8.01b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||10.26|
|Net Profit Margin||16.62%|
How did 539268 perform over the long term?See historical performance and comparison
Is Syngene International undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 539268 (₹548.85) is trading above our estimate of fair value (₹374.87)
Significantly Below Fair Value: 539268 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 539268 is poor value based on its PE Ratio (53.5x) compared to the Indian Life Sciences industry average (21.3x).
PE vs Market: 539268 is poor value based on its PE Ratio (53.5x) compared to the Indian market (21x).
Price to Earnings Growth Ratio
PEG Ratio: 539268 is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: 539268 is overvalued based on its PB Ratio (7.2x) compared to the IN Life Sciences industry average (3.6x).
How is Syngene International forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 539268's forecast earnings growth (26.8% per year) is above the savings rate (6.7%).
Earnings vs Market: 539268's earnings (26.8% per year) are forecast to grow faster than the Indian market (19.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 539268's revenue (19.1% per year) is forecast to grow faster than the Indian market (12.6% per year).
High Growth Revenue: 539268's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 539268's Return on Equity is forecast to be low in 3 years time (16.6%).
How has Syngene International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 539268 has high quality earnings.
Growing Profit Margin: 539268's current net profit margins (16.6%) are lower than last year (17.1%).
Past Earnings Growth Analysis
Earnings Trend: 539268's earnings have grown by 9.2% per year over the past 5 years.
Accelerating Growth: 539268's earnings growth over the past year (14.9%) exceeds its 5-year average (9.2% per year).
Earnings vs Industry: 539268 earnings growth over the past year (14.9%) underperformed the Life Sciences industry 34.7%.
Return on Equity
High ROE: 539268's Return on Equity (13.5%) is considered low.
How is Syngene International's financial position?
Financial Position Analysis
Short Term Liabilities: 539268's short term assets (₹18.8B) exceed its short term liabilities (₹9.4B).
Long Term Liabilities: 539268's short term assets (₹18.8B) exceed its long term liabilities (₹9.1B).
Debt to Equity History and Analysis
Debt Level: 539268's debt to equity ratio (25.7%) is considered satisfactory.
Reducing Debt: 539268's debt to equity ratio has reduced from 77.7% to 25.7% over the past 5 years.
Debt Coverage: 539268's debt is well covered by operating cash flow (85%).
Interest Coverage: 539268 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Syngene International current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 539268's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 539268's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 539268's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 539268's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 539268 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 539268's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jonathan Hunt (52 yo)
Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...
CEO Compensation Analysis
Compensation vs Market: Jonathan's total compensation ($USD869.39K) is above average for companies of similar size in the Indian market ($USD588.59K).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
Experienced Management: 539268's management team is considered experienced (4 years average tenure).
Experienced Board: 539268's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 539268 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Syngene International Limited's employee growth, exchange listings and data sources
- Name: Syngene International Limited
- Ticker: 539268
- Exchange: BSE
- Founded: 1993
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹217.639b
- Shares outstanding: 396.54m
- Website: https://www.syngeneintl.com
Number of Employees
- Syngene International Limited
- Biocon SEZ, Biocon Park,
- Plot No. 2 & 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/27 15:49|
|End of Day Share Price||2021/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.